Over the last 15 years Axel Benner was involved in many prognostic factor tumor studies. He participated in several relevant microarray developments (matrixCGH, aPRIMES). To deal with the heavily increasing amount of biological data and related statistical questions the working group "Statistics for Translational Oncology" was established in 2006. The group concentrates on genomic and proteomic data analysis research and statistical support of pharmaco/toxicogenetic studies for the selection and identification of prognostic and predictive biomarkers and pathways, both, in cancer disease development and treatment. Axel Benner's group is working on the development, usage and validation of statistical methods for the evaluation of function and interaction of genes in cancer development and treatment. For this target we use (combined) microarray technologies to explore and interpret genetic/genomic data. Further focus is on the evaluation of laboratory generated hypotheses in clinical applications using prognostic factor studies and pivotal clinical trials.

My major research areas are statistics for clinical trials, survival analysis, power and sample size calculation, as well as statistics for high-dimensional data.

Nr.	Title
1.	Michel S, Benner A, Tariverdian M, Wentzensen N, Hoefler P, Pommerencke T, Grabe N, von Knebel Doeberitz M, Kloor M. High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. Br J Cancer 2008 99:1867-1873.
2.	Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol. 2009 27: 1627-1636.
3.	Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008 358:1909-1918.
4.	Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthur A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, Hero B, Konig R, Fischer M, Schwab M. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol. 2008 9:R150

A PDF version of the CV is available here.